SynthesisBMC geriatrics2026
Levothyroxine for subclinical hypothyroidism in older adults: no evidence of benefit on quality of life or cardiovascular outcomes: a systematic review.
Synthesis in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubclinical hypothyroidism (SCH) is highly prevalent in older adults, yet the efficacy of levothyroxine treatment in this population remains uncertain. This systematic review evaluated the efficacy of levothyroxine compared with placebo or no treatment on health-related quality of life (HRQoL) and major adverse cardiovascular events (MACE) in older adults with mild SCH.
methodsWe conducted a systematic review following PRISMA 2020 guidelines (PROSPERO: CRD420251176144). We searched PubMed/MEDLINE, Embase, Scopus, Cochrane Library, Web of Science, and LILACS from database inception through October 2025. We included randomized controlled trials (RCTs) and prospective cohort studies in adults ≥ 60 years with SCH (TSH 4.5–10 mIU/L, normal free T4). Two independent reviewers performed study selection, data extraction, and risk of bias assessment (RoB 2 for RCTs, Newcastle-Ottawa Scale for cohorts). Due to substantial heterogeneity in HRQoL instruments and study designs, we performed structured narrative synthesis.
resultsFrom 1,247 identified records, eight studies met inclusion criteria (n = 4,892 participants): two RCTs and six prospective cohort studies with follow-up ranging from 60 to 96 months. RCTs demonstrated no significant benefit of levothyroxine on HRQoL (non-significant differences across all SF-36 and EQ-5D domains) or MACE (RR range: 0.88–0.94; all confidence intervals crossing unity). High-quality cohort studies consistently reported no improvement in HRQoL and no significant reduction in MACE risk after multivariable adjustment (HR range: 0.85–0.95; all 95% CIs including 1.0).
conclusionsCurrent long-term evidence does not support levothyroxine treatment for improving quality of life or reducing cardiovascular events in older adults with mild SCH. These findings support a conservative management strategy of active surveillance over routine treatment in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.